---
id: 229
title: Diabetic Foot Infection (DFI) and Osteomyelitis
category: clinical_syndromes
subcategory: skin_soft_tissue
tags: [diabetic-foot, DFI, osteomyelitis, probe-to-bone, amputation, polymicrobial]
difficulty: high
---

## Question

How are diabetic foot infections managed? Use **"Probe-to-Bone + MRI → Debridement + Polymicrobial Antibiotics (Vanc + Pip-Tazo) × 6 Weeks"** framework.

## Answer

### **Classification (IDSA/IWGDF):**

**Mild:**
- **Superficial ulcer** (skin/subcutaneous only)
- **Erythema <2 cm** around ulcer
- **No systemic signs**

**Moderate:**
- **Deeper infection** (fascia, muscle, tendon)
- **Erythema >2 cm** OR **lymphangitis**
- **No systemic signs**

**Severe:**
- **Systemic toxicity** (fever, hypotension, confusion, vomiting, hyperglycemia)
- **Limb-threatening** (ischemia, gangrene, necrotizing infection)

### **Clinical Presentation:**

**Signs of Infection:**
- **Purulent drainage**
- **Erythema, warmth, swelling, tenderness** (>2 cm from ulcer edge)
- **Foul odor**
- **Exposed bone** (visible or palpable)
- **Systemic signs** (fever, leukocytosis, hyperglycemia)

**Probe-to-Bone Test:**
- **Insert sterile probe** into ulcer base
- **If probe touches bone** → 90% sensitivity, 85% specificity for osteomyelitis
- **Ulcer >2 cm² + ESR >70** also highly predictive

### **Diagnosis:**

**Clinical:**
- **Probe-to-bone positive** + **ulcer >2 cm²** + **ESR >70** → high probability osteomyelitis

**Imaging:**

**X-Ray (First-Line):**
- **Bone destruction, periosteal reaction** (but insensitive early, requires 30-50% bone loss)
- **Gas in soft tissues** (if anaerobes, necrotizing infection)

**MRI (Gold Standard):**
- **Most sensitive/specific** (>90%)
- **Bone marrow edema, cortical destruction, soft tissue involvement**
- **Distinguishes osteomyelitis from Charcot arthropathy**

**Bone Biopsy (ESSENTIAL if Osteomyelitis):**
- **Send for culture** (aerobic + anaerobic, hold 14 days)
- **Do NOT rely on swab/sinus tract culture** (poor correlation)

**Labs:**
- **ESR, CRP** (elevated, non-specific but useful for monitoring)
- **Hemoglobin A1c** (assess glycemic control)
- **ABI (ankle-brachial index)** (assess vascular status)

### **Microbiology:**

**Polymicrobial (80%):**
- **Gram-positives:** *S. aureus* (MSSA/MRSA), *Streptococci*, *Enterococcus*
- **Gram-negatives:** *E. coli*, *Proteus*, *Klebsiella*, *Pseudomonas* (if chronic, prior antibiotics)
- **Anaerobes:** *Bacteroides*, *Peptostreptococcus* (if ischemia, necrosis, foul odor)

**Chronic Ulcers/Prior Antibiotics:**
- **MRSA, ESBL, *Pseudomonas*, VRE**

### **Treatment:**

**1. Wound Care:**

**Offloading:**
- **Total contact cast, walking boot** (reduce pressure on ulcer)

**Debridement:**
- **Sharp debridement** (remove necrotic tissue, callus)
- **If osteomyelitis:** Resect infected bone (if possible)

**Revascularization:**
- **If vascular insufficiency** (ABI <0.5, TcPO₂ <30 mmHg)
- **Vascular surgery consult** (angioplasty, bypass)

**2. Antibiotics:**

**Empiric (Moderate-Severe):**

**Outpatient (Moderate, No MRSA Risk):**
- **Amoxicillin-clavulanate 875mg PO TID**
- **Levofloxacin 750mg PO daily**

**Inpatient (Severe OR MRSA Risk):**
- **Vancomycin 15-20 mg/kg IV q8-12h + pip-tazo 3.375-4.5g IV q6-8h**
- OR **vancomycin + ceftriaxone 2g IV daily + metronidazole 500mg IV q8h**

**If *Pseudomonas* Risk (Chronic, Prior Antibiotics):**
- **Vancomycin + cefepime 2g IV q8h** OR **meropenem 1g IV q8h**

**Pathogen-Directed:**
- **Narrow based on culture/susceptibilities**

**Duration:**
- **Soft tissue only:** 1-2 weeks (mild), 2-3 weeks (moderate-severe)
- **Osteomyelitis:**
  - **With resection** (remove infected bone): 2-5 days post-op
  - **Without resection** (medical management): 6 weeks
  - **Residual dead bone:** May need chronic suppression

**Oral Step-Down (After Clinical Improvement):**
- **High oral bioavailability agents:**
  - *S. aureus* (MSSA): Cephalexin, dicloxacillin, amoxicillin-clavulanate
  - *S. aureus* (MRSA): TMP-SMX, doxycycline, linezolid
  - Gram-negatives: Fluoroquinolones (ciprofloxacin, levofloxacin)

**3. Surgical Management:**

**Indications:**
- **Necrotizing infection** (urgent debridement)
- **Abscess, extensive necrosis**
- **Osteomyelitis with dead bone** (resect infected bone)
- **Limb-threatening infection**
- **Failed medical therapy**

**Amputation (If):**
- **Extensive necrosis, gangrene**
- **Uncontrolled sepsis**
- **Non-viable limb** (severe ischemia, failed revascularization)

### **Special Situations:**

**Osteomyelitis:**
- **Bone biopsy for culture** (do NOT rely on swab)
- **Surgical resection** (if feasible) + short course antibiotics (2-5 days)
- **If no surgery:** Antibiotics × 6 weeks (IV initially, oral step-down)

**Charcot Arthropathy:**
- **NOT infection** (neuropathic osteoarthropathy)
- **Differentiate with MRI** (no bone marrow edema if Charcot alone)
- **Offloading, immobilization**

**Necrotizing Fasciitis:**
- **Rapidly progressive, pain out of proportion, crepitus**
- **See separate card** (urgent surgery + broad-spectrum antibiotics)

### **Prognosis:**

**Amputation Rate:**
- **10-15%** (moderate-severe DFI)
- **Higher if:** Ischemia, extensive necrosis, failed medical/surgical therapy

**Mortality:**
- **5-10%** (severe DFI with sepsis)

**Predictors of Poor Outcome:**
- **Peripheral arterial disease** (ABI <0.5)
- **Extensive bone involvement**
- **ESBL, *Pseudomonas*, MRSA**
- **Poor glycemic control** (A1c >9%)

### **Prevention:**

- **Glycemic control** (A1c <7%)
- **Foot care education** (daily inspection, proper footwear)
- **Treat tinea pedis, calluses**
- **Podiatry referral** (high-risk patients)

## Key Points

### **Probe-to-Bone = High Sensitivity for Osteomyelitis:**
- **90% sensitivity** (if positive, likely osteomyelitis)
- **Ulcer >2 cm² + ESR >70** also predictive

### **MRI = Gold Standard:**
- **Most sensitive/specific** for osteomyelitis
- **Distinguishes from Charcot arthropathy**

### **Bone Biopsy for Culture:**
- **Do NOT rely on swab/sinus tract**
- **Essential if osteomyelitis** (guide therapy)

### **Polymicrobial Coverage:**
- **Vancomycin + pip-tazo** (empiric for moderate-severe)
- **Covers *S. aureus* (MRSA), Gram-negatives, anaerobes**

### **Duration:**
- **Soft tissue:** 1-3 weeks
- **Osteomyelitis (with resection):** 2-5 days post-op
- **Osteomyelitis (no surgery):** 6 weeks

### **Clinical Pearls:**
- **Probe-to-bone** + ulcer >2 cm² + ESR >70 → high probability osteomyelitis
- **MRI gold standard** (distinguishes from Charcot)
- **Bone biopsy for culture** (do NOT swab)
- **Empiric:** Vancomycin + pip-tazo (polymicrobial coverage)
- **Duration:** Soft tissue 1-3 weeks, osteomyelitis 6 weeks (or 2-5 days if resected)
- **Offloading essential** (total contact cast, reduce pressure)
- **Revascularization** if ABI <0.5

## Sources

- [IDSA: Diabetic Foot Infection Guidelines 2024]
- [IWGDF: Diabetic Foot Guidelines 2024]

## Media

N/A
